/
NRSN
$0.71-$0.05 (-6.27%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$27.3M
36M shares
52-week range
$0.63 – $2.19
5% from low
Exchange
NASDAQ
CS
Borrow rate
5.16%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-3.33
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $89.0K | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | −$89.0K | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $898.0K | $2.5M | $3.1M | $6.4M | $7.3M | $5.7M | $6.2M |
| Operating income | −$1.2M | −$2.9M | −$5.6M | −$13.6M | −$12.0M | −$9.9M | −$11.1M |
| EBITDA | −$1.3M | −$2.8M | −$2.9M | −$12.2M | −$9.6M | −$9.9M | −$11.1M |
| Net income | −$1.2M | −$2.8M | −$4.0M | −$12.3M | −$10.1M | −$10.2M | −$11.1M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.22 | -0.51 | -0.23 | -1.07 | -0.83 | -0.55 | -0.44 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $714067 | $-0.39 | $-0.39–$-0.37 | 1 |
| 2027 | $3M | $-0.82 | $-0.82–$-0.82 | 1 |
| 2028 | $13M | $-0.26 | $-0.26–$-0.26 | 1 |
| 2029 | $360M | $1.65 | $1.65–$1.65 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
NeuroSense Therapeutics Ltd. Ordinary Shares
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
www.neurosense-tx.com- Employees
- 16
- IPO / List date
- Dec 9, 2021
Held by traders on TradeandTell
No one on the platform currently holds NRSN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NRSN as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NRSN yet.
